Today’s pressure on pharmaceutical companies reflects greater pressures throughout the entire healthcare ecosystem as payers, patients, and providers wrestle with escalating costs and drive healthcare systems around the world away from being cost-based to becoming value-based. For pharmaceutical companies, this means not only a greater emphasis on creating value, but seeking new ways to capture value as well, particularly at a time when drugs will need to demonstrate they provide benefits commensurate with their costs and governments and payers squeeze down prices. The challenge for drugmakers, broadly speaking, is to both find new ways to create value and capture value.
Full details at the Journal of Commercial Biotechnology
Comments are closed.